Listed Mainboard IPO SAIPARENTERALS

Sai Parenteral's

Sai Parenteral’s IPO is a mainboard public issue of a pharmaceutical company engaged in the manufacturing of branded generic formulations and providing contract development and manufacturing (CDMO) services across domestic and international markets. The IPO comprises a mix of fresh issue (around ₹285 crore) and an offer for sale, with proceeds primarily aimed at capacity expansion, R&D development, debt repayment, and working capital needs. The issue opened on 24 March 2026 and closed on 27 March 2026, with a price band of ₹372–₹392 per share, attracting attention due to its presence in the growing pharmaceutical and export-focused segment. With a diversified product portfolio and improving financial performance, the company operates in a high-growth pharma sector, offering potential long-term opportunities for investors.

IPO Details

Complete IPO information

Current GMP ₹8
Estimated Listing Gain +2.04%
Price Band ₹372.00 - ₹392.00
Issue Price ₹392.00
Listing Price ₹400.00
Lot Size 38 Shares
Issue Type Mainboard
Issue Size TBA
Registrar TBA
Exchange NSE, BSE
Retail Quota TBA
Overall Subscription 0.05x
Listing Date 02 Apr 2026
Minimum Investment ₹14,896
Timeline

IPO roadmap at a glance

Bidding Opens 24 Mar 2026
Bidding Closes 27 Mar 2026
Allotment TBA
Listing 02 Apr 2026
Grey Market Premium

Daily GMP status

Date GMP Change Gain
25 Mar 2026 ₹0.00 - 0.00%
23 Mar 2026 ₹0.00 - 0.00%
19 Mar 2026 ₹0.00 - 0.00%
Swipe to see more →
Market Lot

Application size breakdown

Category Lots Shares Amount
Retail Minimum 1 Lot 38 ₹14,896
Retail Maximum 13 Lot 494 ₹1,93,648
S-HNI Minimum 14 Lot 532 ₹2,08,544
S-HNI Maximum 67 Lot 2,546 ₹9,98,032
B-HNI Minimum 68 Lot 2,584 ₹10,12,928
Analysis

Sai Parenteral’s IPO Details

IPO Open Date March 24, 2026
IPO Close Date March 27, 2026
Face Value ₹5 Per Equity Share
IPO Price Band ₹372 to ₹392 Per Share
Issue Size Approx ₹409 Crores
Fresh Issue Approx ₹285 Crores
Offer for Sale Approx 35,00,000 Equity Shares
Issue Type Book Build Issue
IPO Listing BSE, NSE
Analysis

Sai Parenteral’s IPO Reservation

Investor Category Shares Offered Shares (%)
Anchor Investor — Shares —%
QIB (Ex. Anchor) — Shares 50%
NII — Shares 15%
Retail — Shares 35%
Analysis

Sai Parenteral’s IPO Anchor Investors

Anchor Bidding Date March 23, 2026
Shares Offered — Shares
Anchor Size ₹ — Cr.
Lock-in Period (50% Shares - 30 Days) 2026
Lock-in Period (50% Shares - 90 Days) 2026
Analysis

Sai Parenteral’s IPO Dates

IPO Open Date March 24, 2026
IPO Close Date March 27, 2026
Basis of Allotment March 30, 2026
Refunds April 1, 2026
Credit to Demat Account April 1, 2026
IPO Listing Date April 2, 2026
Bidding Cut-off Time March 27, 2026 – 5 PM
Analysis

Sai Parenteral’s IPO Promoters & Holding Pattern

Particular Shares % Share
Promoter Holding Pre Issue 3,69,08,823 61.23%
Promoter Holding Post Issue 4,41,79,231 -
 
Promoters
Anil Kumar Karusala, Vijitha Gorrepati and Karusala Aruna
Analysis

Sai Parenteral’s IPO – Objects of the Issue

Purpose Amount (₹ Cr.)
Capacity Expansion & Upgradation 110.80
New R&D Centre 18.02
Repayment / Prepayment of Borrowings 20.00
Working Capital Requirements 33.00
Investment in Subsidiary (Singapore) for Acquisition 36.00
General Corporate Purpose
Analysis

About Sai Parenteral’s IPO

Sai Parenteral’s Ltd., founded in 2001, is one of the leading pharmaceutical companies focused on R&D and manufacturing of pharmaceutical products. The firm operates in 2 main business areas: makes and sells its own branded medicines, and also manufactures medicines for other companies internationally. Its product offerings include a wide range of medicines for various health conditions, like cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals, and supplements (VMS), analgesics, and dermatology.
 

Its medicines are available in various forms like tablets, injections, and syrups. Sai Parenteral’s major clients are government agencies, pharmaceutical companies, public and private hospitals, and large distributors in India. The firm operates 5 manufacturing facilities in India, mainly located in Hyderabad, known for developing medicines with international quality certifications.

Analysis

Sai Parenteral’s IPO Company Financial Report

Period Ended Revenue (₹ Cr.) Expense (₹ Cr.) PAT (₹ Cr.) Assets (₹ Cr.)
2023 97.03 89.78 4.38 133.96
2024 155.18 142.63 8.42 268.10
2025 163.74 143.84 14.43 272.39
Sep 2025 89.43 78.27 7.76 376.24
Analysis

Sai Parenteral’s IPO Valuation – FY2025

KPI Values
ROE 15.09%
ROCE 28.92%
EBITDA Margin 24.18%
PAT Margin 8.88%
Debt to Equity
EPS (Basic) ₹5.43
P/E Ratio N/A
RoNW 15.09%
NAV ₹35.98
Analysis

Sai Parenteral’s IPO Peer Group Comparison

Company EPS P/E Ratio RoNW % NAV Income (₹ Cr.)
Sai Life Sciences Limited 8.83 107.70 7.99% 102.12 1,694.57
InnovaCaptab Limited 22.41 32.45 13.37% 167.66 1,243.68
Senores Pharmaceuticals Limited 16.12 64.30 7.18% 176.37 398.25
Gland Pharma Limited 42.40 44.71 7.63% 555.41 5,616.50
Industry Average 62.29
Analysis

IPO Lead Managers aka Merchant Bankers

  • Arihant Capital Markets Ltd. 
FAQ

Sai Parenteral's IPO FAQs

Sai Parenteral's IPO GMP today is Rs 8. Investors can use this GMP along with price band and subscription status for a better IPO review.
Sai Parenteral's IPO price band is Rs 372.00 to Rs 392.00. Check the latest issue price, lot size and GMP together before applying.
Sai Parenteral's IPO open date is 24 Mar 2026, close date is 27 Mar 2026, and listing date is 02 Apr 2026.
Sai Parenteral's IPO lot size is 38 shares. The minimum retail investment is Rs 14,896.
Sai Parenteral's is classified as a Mainboard IPO. This helps investors quickly understand the issue category and exchange segment.
Sai Parenteral's IPO subscription status currently shows Retail 0.03x, QIB 0x, Overall 0.05x.
Sai Parenteral’s IPO is a mainboard public issue of a pharmaceutical company engaged in the manufacturing of branded generic formulations and providing contract development and manufacturing (CDMO) services across domestic and international markets. The IPO comprises a mix of fresh issue (around ₹285 crore) and an offer for sale, with proceeds primarily aimed at capacity expansion, R&D development, debt repayment, and working capital needs. The issue opened on 24 March 2026 and closed on 27 March 2026, with a price band of ₹372–₹392 per share, attracting attention due to its presence in the growing pharmaceutical and export-focused segment. With a diversified product portfolio and improving financial performance, the company operates in a high-growth pharma sector, offering potential long-term opportunities for investors.
Sai Parenteral's IPO issue size is TBA and the expected allotment date is TBA.
Keep Exploring

Similar Recent IPOs

WhatsApp